CoChat
Sign Up
Cited by 20Gestational Diabetes Research and ManagementMicroRNA in disease regulationPancreatic function and diabetes

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Exploring the potential of microRNA as a diagnostic tool for gestational diabetes

Open access
Elhag, Duaa Ahmed, Al Khodor, Souhaila·2023·Journal of Translational Medicine
DOI 10.1186/s12967-023-04269-2PMC PMC10276491
Open this paper in CoChat — free accountOpen PDF

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs that play critical roles in regulating host gene expression. Recent studies have indicated a role of miRNAs in the pathogenesis of gestational diabetes mellitus (GDM), a common pregnancy-related disorder characterized by impaired glucose metabolism. Aberrant expression of miRNAs has been observed in the placenta and/or maternal blood of GDM patients, suggesting their potential use as biomarkers for early diagnosis and prognosis. Additionally, several miRNAs have been shown to modulate key signaling pathways involved in glucose homeostasis, insulin sensitivity, and inflammation, providing insights into the pathophysiology of GDM. This review summarizes the current knowledge on the dynamics of miRNA in pregnancy, their role in GDM as well as their potential as diagnostic and therapeutic targets.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12967-023-04269-2

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Dynamics of the most common significantly dysregulated miRNA in pregnant women with GDM. List of upregulated and downregulated miRNAs during pregnancy progression.
Fig. 1 Dynamics of the most common significantly dysregulated miRNA in pregnant women with GDM. List of upregulated and downregulated miRNAs during pregnancy progression.CC BY · PubMed Central
Fig. 2 Mechanisms of action for the most common significantly dysregulated miRNA in pregnant women with GDM
Fig. 2 Mechanisms of action for the most common significantly dysregulated miRNA in pregnant women with GDMCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 106

  1. Ramachandran A, et al. The Indian diabetes prevention programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49(2):289–97. · DOI · Paper page
  2. Retnakaran R, et al. Glucose intolerance in pregnancy and future risk of pre-diabetes or diabetes. Diabetes Care. 2008;31(10):2026–31. · DOI
  3. Schmidt MI, et al. Gestational diabetes mellitus diagnosed with a 2-h 75-g oral glucose tolerance test and adverse pregnancy outcomes. Diabetes Care. 2001;24(7):1151–5. · DOI
  4. Murgia C, et al. Gestational diabetes mellitus in Sardinia: results from an early, universal screening procedure. Diabetes Care. 2006;29(7):1713–4. · DOI
  5. American Diabetes. 2 Classification and diagnosis of diabetes: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S15–33. · DOI · Paper page
  6. Plasencia W, et al. Criteria for screening and diagnosis of gestational diabetes mellitus in the first trimester of pregnancy. Fetal Diagn Ther. 2011;30(2):108–15. · DOI
  7. Parrettini S, Caroli A, Torlone E. Nutrition and metabolic adaptations in physiological and complicated pregnancy: focus on obesity and gestational diabetes. Front Endocrinol (Lausanne). 2020;11:611929. · DOI
  8. Kohlhepp LM, et al. Physiological changes during pregnancy. Anaesthesist. 2018;67(5):383–96. · DOI
  9. Legare C, et al. Human plasma pregnancy-associated miRNAs and their temporal variation within the first trimester of pregnancy. Reprod Biol Endocrinol. 2022;20(1):14. · DOI
  10. O’Brien J, et al. Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne). 2018;9:402. · DOI · Paper page
  11. Mitchell MD, et al. Placental exosomes in normal and complicated pregnancy. Am J Obstet Gynecol. 2015;213(4 Suppl):S173–81. · DOI
  12. Poirier C, et al. MicroRNAs in pregnancy and gestational diabetes mellitus: emerging role in maternal metabolic regulation. Curr Diab Rep. 2017;17(5):35. · DOI
  13. Cai M, Kolluru GK, Ahmed A. Small molecule, big prospects: MicroRNA in pregnancy and its complications. J Pregnancy. 2017;2017:6972732. · DOI
  14. Akgor U, Ayaz L, Cayan F. Expression levels of maternal plasma microRNAs in preeclamptic pregnancies. J Obstet Gynaecol. 2021;41(6):910–4. · DOI
  15. Salimi S, et al. Association of polymorphisms in miR146a, an inflammation-associated MicroRNA, with the risk of idiopathic recurrent spontaneous miscarriage: a case-control study. Dis Markers. 2022;2022:1495082. · DOI
  16. Kochhar P, et al. microRNA signatures associated with fetal growth restriction: a systematic review. Eur J Clin Nutr. 2022;76(8):1088–102. · DOI
  17. Winger EE, et al. MicroRNAs isolated from peripheral blood in the first trimester predict spontaneous preterm birth. PLoS ONE. 2020;15(8):e0236805. · DOI
  18. Yoffe L, et al. Early detection of preeclampsia using circulating small non-coding RNA. Sci Rep. 2018;8(1):3401. · DOI
  19. So JBY, et al. Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population. Gut. 2021;70(5):829–37. · DOI
  20. Zou R, et al. Development and validation of a circulating microRNA panel for the early detection of breast cancer. Br J Cancer. 2022;126(3):472–81. · DOI
  21. Khan A, et al. Altered circulating microRNAs in patients with diabetic neuropathy and corneal nerve loss: a pilot study. J Clin Med. 2022. https://doi.org/10.3390/jcm11061632. · DOI
  22. Filardi T, et al. Identification and validation of miR-222–3p and miR-409–3p as plasma biomarkers in gestational diabetes mellitus sharing validated target genes involved in metabolic homeostasis. Int J Mol Sci. 2022. https://doi.org/10.3390/ijms23084276. · DOI
  23. Di Cianni G, et al. Prevalence and risk factors for gestational diabetes assessed by universal screening. Diabetes Res Clin Pract. 2003;62(2):131–7. · DOI
  24. Chen L, et al. Influence of acculturation on risk for gestational diabetes among Asian women. Prev Chronic Dis. 2019;16:E158. · DOI
  25. Xiong X, et al. Gestational diabetes mellitus: prevalence, risk factors, maternal and infant outcomes. Int J Gynaecol Obstet. 2001;75(3):221–8. · DOI
  26. Martinez-Ibarra A, et al. Unhealthy levels of phthalates and bisphenol a in Mexican pregnant women with gestational diabetes and its association to altered expression of miRNAs involved with metabolic disease. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20133343. · DOI
  27. Cao YL, et al. Plasma microRNA-16-5p, -17-5p and -20a-5p: novel diagnostic biomarkers for gestational diabetes mellitus. J Obstet Gynaecol Res. 2017;43(6):974–81. · DOI
  28. Juchnicka I, et al. miRNAs as Predictive Factors in Early Diagnosis of Gestational Diabetes Mellitus. Front Endocrinol (Lausanne). 2022;13:839344. · DOI
  29. Sorensen AE, et al. The temporal profile of circulating miRNAs during gestation in overweight and obese women with or without gestational diabetes mellitus. Biomedicines. 2022. https://doi.org/10.3390/biomedicines10020482. · DOI
  30. Stirm L, et al. Maternal whole blood cell miRNA-340 is elevated in gestational diabetes and inversely regulated by glucose and insulin. Sci Rep. 2018;8(1):1366. · DOI
  31. Wander PL, et al. Circulating early- and mid-pregnancy microRNAs and risk of gestational diabetes. Diabetes Res Clin Pract. 2017;132:1–9. · DOI
  32. Gillet V, et al. miRNA profiles in extracellular vesicles from serum early in pregnancies complicated by gestational diabetes mellitus. J Clin Endocrinol Metab. 2019;104(11):5157–69. · DOI
  33. Tagoma A, et al. MicroRNA profiling of second trimester maternal plasma shows upregulation of miR-195-5p in patients with gestational diabetes. Gene. 2018;672:137–42. · DOI
  34. Sebastiani G, et al. Circulating microRNA (miRNA) expression profiling in plasma of patients with gestational diabetes mellitus reveals upregulation of miRNA miR-330-3p. Front Endocrinol (Lausanne). 2017;8:345. · DOI
  35. Pfeiffer S, et al. Circulating miR-330-3p in late pregnancy is associated with pregnancy outcomes among lean women with GDM. Sci Rep. 2020;10(1):908. · DOI
  36. Pheiffer C, et al. Decreased expression of circulating miR-20a-5p in South African women with gestational diabetes mellitus. Mol Diagn Ther. 2018;22(3):345–52. · DOI
  37. Bhushan R, et al. MicroRNA-7 regulates insulin signaling pathway by targeting IRS1, IRS2, and RAF1 genes in gestational diabetes mellitus. Microrna. 2022;11(1):57–72. · DOI
  38. Balci S, et al. Expression level of miRNAS in patients with gestational diabetes. Turkish J Biochem. 2020;45(6):825–31. · DOI
  39. Zhang X, et al. Association of gestational diabetes mellitus and abnormal vaginal flora with adverse pregnancy outcomes. Medicine (Baltimore). 2018;97(34):e11891. · DOI
  40. Kong L, et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol. 2011;48(1):61–9. · DOI
  41. Wang F, Zhang X, Zhou H. Role of cell free microRNA-19a and microRNA-19b in gestational diabetes mellitus patients. 3 Biotech. 2019;9(11):406. · DOI
  42. Zhu Y, et al. Profiling maternal plasma microRNA expression in early pregnancy to predict gestational diabetes mellitus. Int J Gynaecol Obstet. 2015;130(1):49–53. · DOI
  43. Perucci LO, et al. Soluble endoglin, transforming growth factor-Beta 1 and soluble tumor necrosis factor alpha receptors in different clinical manifestations of preeclampsia. PLoS ONE. 2014;9(5):e97632. · DOI
  44. Kumar A, et al. Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism. Diabetes. 2010;59(6):1397–406. · DOI
  45. Gao X, Zhao S. miRNA-16-5p inhibits the apoptosis of high glucose-induced pancreatic beta cells via targeting of CXCL10: potential biomarkers in type 1 diabetes mellitus. Endokrynol Pol. 2020;71(5):404–10. · DOI
  46. Ye EA, Steinle JJ. miR-15b/16 protects primary human retinal microvascular endothelial cells against hyperglycemia-induced increases in tumor necrosis factor alpha and suppressor of cytokine signaling 3. J Neuroinflammation. 2015;12:44. · DOI
  47. Carew RM, et al. Insulin receptor substrate 2 and FoxO3a signalling are involved in E-cadherin expression and transforming growth factor-beta1-induced repression in kidney epithelial cells. FEBS J. 2011;278(18):3370–80. · DOI
  48. Geng Y, et al. Insulin receptor substrate 1/2 (IRS1/2) regulates Wnt/beta-catenin signaling through blocking autophagic degradation of dishevelled2. J Biol Chem. 2014;289(16):11230–41. · DOI
  49. Hubal MJ, et al. Circulating adipocyte-derived exosomal MicroRNAs associated with decreased insulin resistance after gastric bypass. Obesity (Silver Spring). 2017;25(1):102–10. · DOI
  50. Guarino E, et al. Circulating MicroRNAs as biomarkers of gestational diabetes mellitus: updates and perspectives. Int J Endocrinol. 2018;2018:6380463. · DOI
  51. Eyileten C, et al. Alteration of circulating platelet-related and diabetes-related microRNAs in individuals with type 2 diabetes mellitus: a stepwise hypoglycaemic clamp study. Cardiovasc Diabetol. 2022;21(1):79. · DOI
  52. Liang X, et al. MicroRNA-16 suppresses the activation of inflammatory macrophages in atherosclerosis by targeting PDCD4. Int J Mol Med. 2016;37(4):967–75. · DOI · Paper page
  53. Yang Y, et al. miR-16 inhibits NLRP3 inflammasome activation by directly targeting TLR4 in acute lung injury. Biomed Pharmacother. 2019;112:108664. · DOI
  54. Wang W, et al. Preeclampsia up-regulates angiogenesis-associated microRNA (i.e., miR-17, -20a, and -20b) that target ephrin-B2 and EPHB4 in human placenta. J Clin Endocrinol Metab. 2012;97(6):E1051-9. · DOI
  55. Li L, et al. Correlation between alterations of gut microbiota and miR-122-5p expression in patients with type 2 diabetes mellitus. Ann Transl Med. 2020;8(22):1481. · DOI
  56. Nuriel-Ohayon M, Neuman H, Koren O. Microbial changes during pregnancy, birth, and infancy. Front Microbiol. 2016;7:1031. · DOI
  57. Wang M. miR-433 protects pancreatic beta cell growth in high-glucose conditions. Mol Med Rep. 2017;16(3):2604–10. · DOI
  58. Badacz R, et al. Expression of miR-1–3p, miR-16–5p and miR-122–5p as possible risk factors of secondary cardiovascular events. Biomedicines. 2021. https://doi.org/10.3390/biomedicines9081055. · DOI
  59. Bhatt MP, et al. C-peptide activates AMPKalpha and prevents ROS-mediated mitochondrial fission and endothelial apoptosis in diabetes. Diabetes. 2013;62(11):3851–62. · DOI
  60. Brosens JJ, Pijnenborg R, Brosens IA. The myometrial junctional zone spiral arteries in normal and abnormal pregnancies: a review of the literature. Am J Obstet Gynecol. 2002;187(5):1416–23. · DOI
  61. Li J, et al. MicroRNA-17–5p acts as a biomarker and regulates mitochondrial dynamics in trophoblasts and endothelial cells by targeting the mitofusins Mfn1/Mfn2 in gestational diabetes mellitus. Archiv Med Sci. 2022. https://doi.org/10.5114/aoms/145778. · DOI
  62. Dziedzic EA, et al. Vitamin D level is associated with severity of coronary artery atherosclerosis and incidence of acute coronary syndromes in non-diabetic cardiac patients. Arch Med Sci. 2019;15(2):359–68. · DOI
  63. Sorensen AE, et al. The predictive value of miR-16, -29a and -134 for early identification of gestational diabetes: a nested analysis of the DALI Cohort. Cells. 2021. https://doi.org/10.3390/cells10010170. · DOI
  64. Nair S, et al. Extracellular vesicle-associated miRNAs are an adaptive response to gestational diabetes mellitus. J Transl Med. 2021;19(1):360. · DOI
  65. Hod M, et al. The international federation of Gynecology and obstetrics (FIGO) initiative on gestational diabetes mellitus: a pragmatic guide for diagnosis, management, and care. Int J Gynaecol Obstet. 2015;131(Suppl 3):S173-211. · DOI · Paper page
  66. Chen Y, et al. Exosomal microRNA miR-92a concentration in serum reflects human brown fat activity. Nat Commun. 2016;7:11420. · DOI
  67. Chondronikola M, et al. Brown adipose tissue improves whole-body glucose homeostasis and insulin sensitivity in humans. Diabetes. 2014;63(12):4089–99. · DOI
  68. Lamadrid-Romero M, et al. Central nervous system development-related microRNAs levels increase in the serum of gestational diabetic women during the first trimester of pregnancy. Neurosci Res. 2018;130:8–22. · DOI
  69. Collares CV, et al. Identifying common and specific microRNAs expressed in peripheral blood mononuclear cell of type 1, type 2, and gestational diabetes mellitus patients. BMC Res Notes. 2013;6:491. · DOI
  70. Zhang T, Ji C, Shi R. miR-142-3p promotes pancreatic beta cell survival through targeting FOXO1 in gestational diabetes mellitus. Int J Clin Exp Pathol. 2019;12(5):1529–38.
  71. Kitamura T. The role of FOXO1 in beta-cell failure and type 2 diabetes mellitus. Nat Rev Endocrinol. 2013;9(10):615–23. · DOI
  72. Prats-Puig A, et al. Changes in circulating microRNAs are associated with childhood obesity. J Clin Endocrinol Metab. 2013;98(10):E1655–60. · DOI
  73. Al-Rawaf HA. Circulating microRNAs and adipokines as markers of metabolic syndrome in adolescents with obesity. Clin Nutr. 2019;38(5):2231–8. · DOI
  74. Prabu P, et al. Circulating MiRNAs of “Asian Indian Phenotype” identified in subjects with impaired glucose tolerance and patients with type 2 diabetes. PLoS ONE. 2015;10(5):e0128372. · DOI
  75. Liang YZ, et al. Identification of neuroendocrine stress response-related circulating MicroRNAs as biomarkers for type 2 diabetes mellitus and insulin resistance. Front Endocrinol (Lausanne). 2018;9:132. · DOI
  76. Zhu H, et al. The Lin28/let-7 axis regulates glucose metabolism. Cell. 2011;147(1):81–94. · DOI
  77. Jiang LQ, et al. Autocrine role of interleukin-13 on skeletal muscle glucose metabolism in type 2 diabetic patients involves microRNA let-7. Am J Physiol Endocrinol Metab. 2013;305(11):E1359–66. · DOI
  78. Wang J, et al. Serum miR-195-5p is upregulated in gestational diabetes mellitus. J Clin Lab Anal. 2020;34(8):e23325. · DOI
  79. Karolina DS, et al. Circulating miRNA profiles in patients with metabolic syndrome. J Clin Endocrinol Metab. 2012;97(12):E2271–6. · DOI
  80. Nair S, et al. Human placental exosomes in gestational diabetes mellitus carry a specific set of miRNAs associated with skeletal muscle insulin sensitivity. Clin Sci (Lond). 2018;132(22):2451–67. · DOI
  81. Herrera-Van Oostdam AS, et al. Placental exosomes isolated from urine of patients with gestational diabetes exhibit a differential profile expression of microRNAs across gestation. Int J Mol Med. 2020;46(2):546–60. · DOI
  82. Ibarra A, et al. Diabetes in pregnancy and MicroRNAs: promises and limitations in their clinical application. Noncodind RNA. 2018. https://doi.org/10.3390/ncrna4040032. · DOI
  83. Shi Z, et al. Differential expression of microRNAs in omental adipose tissue from gestational diabetes mellitus subjects reveals miR-222 as a regulator of ERalpha expression in estrogen-induced insulin resistance. Endocrinology. 2014;155(5):1982–90. · DOI
  84. Abdeltawab A, et al. Circulating micro RNA-223 and angiopoietin-like protein 8 as biomarkers of gestational diabetes mellitus. Br J Biomed Sci. 2021;78(1):12–7. · DOI
  85. Nielsen LB, et al. Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression. Exp Diabetes Res. 2012;2012:896362.
  86. Xu K, et al. microRNA-503 contribute to pancreatic beta cell dysfunction by targeting the mTOR pathway in gestational diabetes mellitus. EXCLI J. 2017;16:1177–87.
  87. Wen J, Bai X. miR-520h Inhibits cell survival by targeting mTOR in gestational diabetes mellitus. Acta Biochim Pol. 2021;68(1):65–70.
  88. Wang P, et al. Dysregulation of microRNA-657 influences inflammatory response via targeting interleukin-37 in gestational diabetes mellitus. J Cell Physiol. 2019;234(5):7141–8. · DOI
  89. Wang P, et al. miR-657 promotes macrophage polarization toward M1 by targeting FAM46C in gestational diabetes mellitus. Mediators Inflamm. 2019;2019:4851214. · DOI
  90. Peng HY, Li HP, Li MQ. High glucose induces dysfunction of human umbilical vein endothelial cells by upregulating miR-137 in gestational diabetes mellitus. Microvasc Res. 2018;118:90–100. · DOI
  91. Li J, et al. A MicroRNA signature in gestational diabetes mellitus associated with risk of macrosomia. Cell Physiol Biochem. 2015;37(1):243–52. · DOI · Paper page
  92. Hocaoglu M, et al. Identification of miR-16-5p and miR-155-5p microRNAs differentially expressed in circulating leukocytes of pregnant women with polycystic ovary syndrome and gestational diabetes. Gynecol Endocrinol. 2021;37(3):216–20. · DOI
  93. Sun DG, et al. The miRNA-29b Is downregulated in placenta during gestational diabetes mellitus and may alter placenta development by regulating trophoblast migration and invasion through a HIF3A-dependent mechanism. Front Endocrinol (Lausanne). 2020;11:169. · DOI
  94. Zhang L, et al. Down-regulation of microRNA-30d-5p is associated with gestational diabetes mellitus by targeting RAB8A. J Diabetes Complicat. 2021;35(8):107959. · DOI
  95. Hocaoglu M, et al. Differential expression of candidate circulating microRNAs in maternal blood leukocytes of the patients with preeclampsia and gestational diabetes mellitus. Pregnancy Hypertens. 2019;17:5–11. · DOI
  96. He Y, et al. miR-494 protects pancreatic beta-cell function by targeting PTEN in gestational diabetes mellitus. EXCLI J. 2017;16:1297–307.
  97. Pheiffer C, et al. MicroRNA profiling in HIV-infected South African women with gestational diabetes mellitus. Mol Diagn Ther. 2019;23(4):499–505. · DOI
  98. Florio MC, et al. Aging, MicroRNAs, and heart failure. Curr Probl Cardiol. 2020;45(12):100406. · DOI
  99. Krek A, et al. Combinatorial microRNA target predictions. Nat Genet. 2005;37(5):495–500. · DOI · Paper page
  100. Bovell LC, et al. The prognostic value of microRNAs varies with patient race/ethnicity and stage of colorectal cancer. Clin Cancer Res. 2013;19(14):3955–65. · DOI
  101. Karere GM, et al. Sex Differences in MicroRNA expression and cardiometabolic risk factors in hispanic adolescents with obesity. J Pediatr. 2021;235:138-143 e5. · DOI
  102. Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nat Rev Genet. 2012;13(5):358–69. · DOI · Paper page
  103. Wang K, et al. Comparing the MicroRNA spectrum between serum and plasma. PLoS ONE. 2012;7(7):e41561. · DOI
  104. Dias S, et al. MicroRNA expression varies according to glucose tolerance, measurement platform, and biological source. Biomed Res Int. 2017;2017:1080157. · DOI
  105. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20. · DOI · Paper page
  106. Yu X, et al. miR-96-5p: A potential diagnostic marker for gestational diabetes mellitus. Medicine (Baltimore). 2021;100(21):e25808. · DOI

Cited by

Sorted by citations

Metadata

Authors
Elhag, D. A., & Al Khodor, S.
Affiliations
Sidra Medical and Research Center (QA)
ORCID
Venue
Journal of Translational Medicine
Publisher
Springer Science and Business Media LLC
Published
2023-06-17
Volume
21
Issue
1
Pages
392-392
ISSN
1479-5876 (ISSN-L)
DOI
10.1186/s12967-023-04269-2
PMC
PMC10276491
OpenAlex
W4381085639
Cited by
20
References
5
Citations by year
2026: 9 · 2025: 6 · 2024: 4 · 2023: 1
FWCI
1.22
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Translational Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
Sidra Medical and Research Center
Topics
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
microRNA, gestational diabetes mellitus, diagnostic biomarkers, early diagnosis, glucose homeostasis, insulin sensitivity, inflammation, placenta, maternal blood, therapeutic target, pregnancy
MeSH terms
Female, Humans, Insulin Resistance, Placenta, Pregnancy, Pregnancy Complications, Diabetes, Gestational, MicroRNAs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review